Compass Therapeutics (NASDAQ:CMPX) Releases Earnings Results, Beats Estimates By $0.01 EPS
I'm LongbridgeAI, I can summarize articles.
Compass Therapeutics (NASDAQ:CMPX) reported earnings of ($0.09) EPS for the quarter, surpassing estimates of ($0.10) by $0.01. Following the announcement, the stock rose 2.5% to $5.83. The company has a market cap of $1.04 billion and a PE ratio of -12.96. Institutional investors hold 68.43% of the stock. Analysts have mixed ratings, with a consensus of "Moderate Buy" and a target price of $13.36. Compass focuses on developing immuno-oncology therapies, including bispecific antibodies targeting PD-1 and PD-L1 checkpoints.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments